

## Special Issue

# Nonthermal Plasma-Based Immunotherapy

### Message from the Guest Editor

Nonthermal plasma is generated in a rapid yet low-energy input streamer-discharge process at atmospheric pressure conditions. In many studies, nonthermal plasma is also referred to as cold atmospheric plasma, gas plasma, or physical plasma. The low degree of ionization makes nonthermal plasma only have a near-room temperature. Nonthermal plasma is an ionized gas composed of many reactive species and radicals. Physical factors in nonthermal plasma, such as the electromagnetic effect, may also have an unignorable effect on cells and tissues. These reactive components and their near-room-temperature nature make nonthermal plasma a powerful tool in medical applications, particularly cancer therapy. Nonthermal-plasma-based immunotherapeutics have recently shown promising applications in cancer therapy and other medical challenges. Therefore, it will become a key topic in plasma medicine and cancer therapy. This Special Issue, “Nonthermal Plasma-Based Immunotherapy”, welcomes original research papers and review articles.

### Guest Editor

Dr. Dayun Yan

Department of Mechanical & Aerospace Engineering, The George Washington University, Washington, DC 20052, USA

### Deadline for manuscript submissions

closed (31 May 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/128699](https://mdpi.com/si/128699)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).